CHINARES PHARMA (03320): China Resources Double-Crane Pharmaceutical's net profit for the first three quarters was approximately RMB1.307 billion, a year-on-year decrease of 6.51%.
China Resources Pharmaceutical (03320) announced the first three quarters of 2026 results for China Resources Double-Crane Pharmaceutical, with total operating revenue of approximately RMB8.066 billion, a year-on-year decrease of 4%; net profit of approximately RMB1.307 billion, a year-on-year decrease of 6.51%.
CHINARES PHARMA (03320) announced the results of China Resources Double-Crane Pharmaceutical for the first three quarters of 2026: total operating revenue was approximately RMB8.066 billion, a year-on-year decrease of 4%; net profit was approximately RMB1.307 billion, a year-on-year decrease of 6.51%.
Related Articles
CHINA RISUN GP (01907) repurchased 1 million shares for HK$1.5418 million on October 27.
CH MODERN D (01117) subsidiary completes issuance of RMB500 million medium-term notes
Stellantis (STLA.US) shares and bonds both hit record lows, with Wednesday's earnings report becoming a battle to defend the CEO's credibility.
CHINA RISUN GP (01907) repurchased 1 million shares for HK$1.5418 million on October 27.
CH MODERN D (01117) subsidiary completes issuance of RMB500 million medium-term notes
Stellantis (STLA.US) shares and bonds both hit record lows, with Wednesday's earnings report becoming a battle to defend the CEO's credibility.
